New insights into the mechanisms of venous thrombosis.

Venous thrombosis is a leading cause of morbidity and mortality in industrialized countries, especially in the elderly. Many risk factors have been identified for venous thrombosis that alter blood flow, activate the endothelium, and increase blood coagulation. However, the precise mechanisms that trigger clotting in large veins have not been fully elucidated. The most common site for initiation of the thrombus appears to be the valve pocket sinus, due to its tendency to become hypoxic. Activation of endothelial cells by hypoxia or possibly inflammatory stimuli would lead to surface expression of adhesion receptors that facilitate the binding of circulating leukocytes and microvesicles. Subsequent activation of the leukocytes induces expression of the potent procoagulant protein tissue factor that triggers thrombosis. Understanding the mechanisms of venous thrombosis may lead to the development of new treatments.

[1]  D. Lombardo,et al.  Cancer cell–derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo , 2009, The Journal of experimental medicine.

[2]  T. Wakefield,et al.  Critical review of mouse models of venous thrombosis. , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[3]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[4]  G. Lip,et al.  Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation , 2009 .

[5]  A. Iorio,et al.  Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. , 2010, Archives of internal medicine.

[6]  P. Romundstad,et al.  Incidence and mortality of venous thrombosis: a population‐based study , 2007, Journal of thrombosis and haemostasis : JTH.

[7]  A. Wolberg,et al.  Plasma and cellular contributions to fibrin network formation, structure and stability , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  Vandenbroucke UvA-DARE ( Digital Academic Repository ) Oral contraceptives and the risk of venous thrombosis , 2001 .

[9]  R. Cummings,et al.  Role of PSGL-1 binding to selectins in leukocyte recruitment. , 1997, The Journal of clinical investigation.

[10]  S. Basili,et al.  Inhibition of tissue-factor-mediated thrombin generation by simvastatin. , 2000, Atherosclerosis.

[11]  D. Johns,et al.  Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. , 2012, The Journal of clinical investigation.

[12]  E. Oger,et al.  Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case–control study , 2004, Fundamental & clinical pharmacology.

[13]  N. Mackman,et al.  Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[14]  C. Gonsalves,et al.  May-Thurner Syndrome: Case Report and Review of the Literature Involving Modern Endovascular Therapy , 2009, Vascular.

[15]  T. Mayadas,et al.  Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. , 1996, The Journal of clinical investigation.

[16]  E. Tremoli,et al.  Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. , 2007, Pharmacological research.

[17]  R. Hubbard,et al.  Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting , 2006, The Lancet.

[18]  Jean-MarieFreyssinet,et al.  Cellular Mechanisms Underlying the Formation of Circulating Microparticles , 2011 .

[19]  W M O'Fallon,et al.  Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.

[20]  C. Benjamin,et al.  Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets , 1992, Nature.

[21]  W. Aird,et al.  Vascular-bed--specific hemostasis and hypercoagulable states. , 1999, The New England journal of medicine.

[22]  T. Wakefield,et al.  Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation , 2008, Thrombosis and Haemostasis.

[23]  D. Neuberg,et al.  Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy , 2009, Clinical Cancer Research.

[24]  T. Renné,et al.  Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In Vivo , 2009, Cell.

[25]  S. Jackson Arterial thrombosis—insidious, unpredictable and deadly , 2011, Nature Medicine.

[26]  A. Clemens,et al.  Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[27]  K. Steinbeck,et al.  Increased tissue factor activity in monocytes from obese young adults , 2010, Clinical and experimental pharmacology & physiology.

[28]  C. Esmon The protein C pathway. , 2003, Critical care medicine.

[29]  G. Broze,et al.  Tissue Factor Pathway Inhibitor , 1995, Thrombosis and Haemostasis.

[30]  E. Horváth-Puhó,et al.  Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study , 2009, Journal of thrombosis and haemostasis : JTH.

[31]  D. Wagner,et al.  Neutrophil extracellular traps promote deep vein thrombosis in mice , 2012, Journal of thrombosis and haemostasis : JTH.

[32]  P. Libby,et al.  An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.

[33]  K. Mann,et al.  The dynamics of thrombin formation. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[34]  M. Baker,et al.  Effect of anatomic variations on deep venous thrombosis of the lower extremity. , 1986, AJR. American journal of roentgenology.

[35]  W. Bargar,et al.  Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. , 1998, Archives of internal medicine.

[36]  F. Rosendaal,et al.  HMG‐CoA reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.

[37]  S. Watson Platelet activation by extracellular matrix proteins in haemostasis and thrombosis. , 2009, Current pharmaceutical design.

[38]  G. Raskob,et al.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[39]  A. Bloom Haemostasis and thrombosis , 1981 .

[40]  M. Prins,et al.  Increased Fibrinolytic Activity during Use of Oral Contraceptives Is Counteracted by an Enhanced Factor XI-independent down Regulation of Fibrinolysis , 2000, Thrombosis and Haemostasis.

[41]  E. Myers,et al.  Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. , 2006, American journal of obstetrics and gynecology.

[42]  Alberto Smith,et al.  Leukocytes and the natural history of deep vein thrombosis: current concepts and future directions. , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[43]  N. Mackman,et al.  Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. , 2010, Thrombosis research.

[44]  A. Khorana Venous thromboembolism and prognosis in cancer. , 2010, Thrombosis research.

[45]  F. Rosendaal,et al.  Venous thrombosis in the elderly , 2007, Journal of thrombosis and haemostasis : JTH.

[46]  B. Osterud,et al.  Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes. , 2009, Scandinavian journal of haematology.

[47]  S. Shirasawa,et al.  Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. , 2005, Blood.

[48]  Sanjiv J. Shah,et al.  Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. , 2011, Thrombosis research.

[49]  N. Key,et al.  Current treatment of venous thromboembolism. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[50]  R. Cummings,et al.  Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. , 1997, The Journal of clinical investigation.

[51]  B. Furie,et al.  Mechanisms of thrombus formation. , 2008, The New England journal of medicine.

[52]  C. Esmon,et al.  Valves of the deep venous system: an overlooked risk factor. , 2007, Blood.

[53]  S. Goldhaber Epidemiology of pulmonary embolism. , 2001, Seminars in vascular medicine.

[54]  M. Woodward,et al.  EPIDEMIOLOGY OF COAGULATION FACTORS, INHIBITORS AND ACTIVATION MARKERS: THE THIRD GLASGOW MONICA SURVEY I. ILLUSTRATIVE REFERENCE RANGES BY AGE, SEX AND HORMONE USE , 1997, British journal of haematology.

[55]  S. Eichinger,et al.  Deep vein thrombosis , 2005, The Lancet.

[56]  C HISCOCK,et al.  EPIDEMICS OF TYPHOID FEVER. , 1964, Lancet.

[57]  C. Esmon The regulation of natural anticoagulant pathways , 1987, Science.

[58]  T. Renné,et al.  The intrinsic pathway of coagulation: a target for treating thromboembolic disease? , 2007, Journal of thrombosis and haemostasis : JTH.

[59]  S. Robson,et al.  Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets. , 2006, Blood cells, molecules & diseases.

[60]  A. James Venous thromboembolism in pregnancy. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[61]  James H Morrissey,et al.  Polyphosphate exerts differential effects on blood clotting, depending on polymer size. , 2010, Blood.

[62]  M. Thomas,et al.  The iliac compression syndrome , 1965, The British journal of surgery.

[63]  T. Lau,et al.  Venous Thromboembolism in Pregnant Chinese Women , 2001, Obstetrics and gynecology.

[64]  N. Mackman Triggers, targets and treatments for thrombosis , 2008, Nature.

[65]  N. Mackman,et al.  Microparticles in Hemostasis and Thrombosis , 2011, Circulation research.

[66]  S. Noble,et al.  Epidemiology and pathophysiology of cancer-associated thrombosis , 2010, British Journal of Cancer.

[67]  Nigel Mackman,et al.  Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. , 2004, Blood.

[68]  Paul Enright,et al.  Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. , 2004, The American journal of medicine.

[69]  J. Hoover-Plow,et al.  The functions of plasminogen in cardiovascular disease. , 2004, Trends in cardiovascular medicine.

[70]  K. Bauer,et al.  Role of antithrombin III as a regulator of in vivo coagulation. , 1991, Seminars in hematology.

[71]  K. Bremme Haemostatic changes in pregnancy. , 2003, Best practice & research. Clinical haematology.

[72]  Anetta Undas,et al.  Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[73]  S. Basili,et al.  Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia , 1997, The Lancet.

[74]  L. Melton,et al.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.

[75]  A. D’Angelo,et al.  The protein C pathway and sepsis. , 2012, Thrombosis research.

[76]  G. Broze Tissue Factor Pathway Inhibitor , 1995, Thrombosis and Haemostasis.

[77]  M. Prins,et al.  Effects on Coagulation of Levonorgestrel- and Desogestrel-containing Low Dose Oral Contraceptives: a Cross-over Study , 2000, Thrombosis and Haemostasis.

[78]  P. Reitsma,et al.  Genetics of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.

[79]  James H Morrissey,et al.  Polyphosphate modulates blood coagulation and fibrinolysis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[80]  K. Preissner,et al.  Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation , 2007, Proceedings of the National Academy of Sciences.

[81]  A. Khorana,et al.  Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer , 2008, Journal of thrombosis and haemostasis : JTH.

[82]  J. Emmerich,et al.  Venous Thromboembolism: Risk Factors for Recurrence , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[83]  G. Johnson,et al.  Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty , 2009, Thrombosis and Haemostasis.

[84]  B. Lämmle,et al.  von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. , 2011, Blood.

[85]  D. W. Barritt,et al.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. , 1960, Lancet.

[86]  WolfgangMueck,et al.  Rivaroxaban: A New Oral Factor Xa Inhibitor , 2010 .

[87]  A. van der Vliet,et al.  Venous valvular stasis-associated hypoxia and thrombosis: what is the link? , 2011, Annual review of physiology.

[88]  J. Eikelboom,et al.  Update on Antithrombotic Therapy: New Anticoagulants , 2010, Circulation.

[89]  N. Mackman Role of tissue factor in hemostasis, thrombosis, and vascular development. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[90]  P. Libby,et al.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.

[91]  P. Reitsma,et al.  Mechanistic View of Risk Factors for Venous Thromboembolism , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[92]  Z. Ruggeri,et al.  The role of von Willebrand factor in thrombus formation. , 2007, Thrombosis research.

[93]  A. Marcus,et al.  The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. , 1997, The Journal of clinical investigation.

[94]  M. Cybulsky,et al.  Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.

[95]  K. Preissner,et al.  Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases , 2010, Nature Medicine.

[96]  M. Dávila,et al.  Tissue Factor-Bearing Microparticles Derived from Tumor Cells: Impact on Coagulation Activation. , 2006 .

[97]  A. Walch,et al.  Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo , 2012, The Journal of experimental medicine.

[98]  P. Fontana,et al.  Cell-derived microparticles in haemostasis and vascular medicine , 2009, Thrombosis and Haemostasis.

[99]  J. Hartwig,et al.  Extracellular DNA traps promote thrombosis , 2010, Proceedings of the National Academy of Sciences.

[100]  C. Esmon,et al.  Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. , 1987, The Journal of clinical investigation.

[101]  E. Oger Incidence of Venous Thromboembolism: A Community-based Study in Western France , 2000, Thrombosis and Haemostasis.

[102]  Chaoyang Li,et al.  Increasing Trends in Waist Circumference and Abdominal Obesity among U.S. Adults , 2007, Obesity.

[103]  K Konstantopoulos,et al.  Perspectives Series: Cell Adhesion in Vascular Biology Effects of Fluid Dynamic Forces on Vascular Cell Adhesion , 1996 .

[104]  G. Soff A New Generation of Oral Direct Anticoagulants , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[105]  C. Marosi,et al.  Prediction of venous thromboembolism in cancer patients. , 2010, Blood.

[106]  H. Meiselman,et al.  A local increase in red blood cell aggregation can trigger deep vein thrombosis: evidence based on quantitative cellular ultrasound imaging , 2011, Journal of thrombosis and haemostasis : JTH.

[107]  N. Mackman Tissue-Specific Hemostasis in Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[108]  M. Gent,et al.  Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty , 2010, Thrombosis and Haemostasis.

[109]  M. Allman-Farinelli Obesity and venous thrombosis: a review. , 2011, Seminars in thrombosis and hemostasis.

[110]  C. Esmon,et al.  The link between vascular features and thrombosis. , 2011, Annual review of physiology.

[111]  C. O. Kennedy A controlled trial , 1971, British Homeopathic Journal.

[112]  F. Rosendaal,et al.  Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use , 2003, Thrombosis and Haemostasis.

[113]  I. Silver,et al.  The PO2 in venous valve pockets: Its possible bearing on thrombogenesis , 1981, The British journal of surgery.

[114]  G. Lip,et al.  The hypercoagulable state of malignancy: pathogenesis and current debate. , 2002, Neoplasia.

[115]  T. Wakefield,et al.  Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes. , 2009, Thrombosis research.

[116]  J. Chou,et al.  Accumulation of Tissue Factor into Developing Thrombi In Vivo Is Dependent upon Microparticle P-Selectin Glycoprotein Ligand 1 and Platelet P-Selectin , 2003, The Journal of experimental medicine.

[117]  R. Bertina,et al.  Microparticle‐associated tissue factor activity in cancer patients with and without thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.

[118]  G. Newton,et al.  Emerging mechanisms of neutrophil recruitment across endothelium. , 2011, Trends in immunology.

[119]  R. Virchow,et al.  Gesammelte Abhandlungen zur wissenschaftlichen Medicin , 1856 .

[120]  W. Fay Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. , 2004, Trends in cardiovascular medicine.

[121]  E. Tremoli,et al.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[122]  G. Lippi,et al.  Arterial thrombus formation in cardiovascular disease , 2011, Nature Reviews Cardiology.

[123]  T. Wakefield,et al.  Mechanisms of venous thrombosis and resolution. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[124]  R. Bertina,et al.  Microparticle-Associated Tissue Factor Activity: A Link between Cancer and Thrombosis?. , 2005 .